Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$17.28M$17.28M+103.0% vs Q2 2017 Net Income-$38.67M-$38.67MN/M vs Q2 2017 EPS Diluted-$0.54-$0.54N/M vs Q2 2017 Gross Profit$12,046,000+60.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$60,729,000N/M Free Cash Flowderived-$62,063,000N/M Margins · derivedGross margin69.7%−18.4 pt vs Q2 2017
Operating margin-224.9%+269.3 pt vs Q2 2017
Net margin-223.8%+279.1 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 8, 2018 · 39 d after period end